A next-generation GMMA-based vaccine candidate to fight shigellosis

[1]  M. Pizza,et al.  Functional assays to evaluate antibody-mediated responses against Shigella: a review , 2023, Frontiers in Cellular and Infection Microbiology.

[2]  C. MacLennan,et al.  Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data , 2022, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  P. Njuguna,et al.  Complement-mediated serum bactericidal activity of antibodies elicited by the Shigella sonnei GMMA vaccine in adults from a shigellosis-endemic country: Exploratory analysis of a Phase 2a randomized study , 2022, Frontiers in Immunology.

[4]  C. MacLennan,et al.  Frontiers in Shigella Vaccine Development , 2022, Vaccines.

[5]  E. Bartolini,et al.  Antigen presentation by Follicular Dendritic cells to cognate B cells is pivotal for Generalised Modules for membrane antigens (GMMA) immunogenicity. , 2022, Vaccine.

[6]  C. MacLennan,et al.  The Shigella Vaccines Pipeline , 2022, Vaccines.

[7]  Francesco Berlanda Scorza,et al.  Towards a Four-Component GMMA-Based Vaccine against Shigella , 2022, Vaccines.

[8]  F. Necchi,et al.  Impact of O-Acetylation on S. flexneri 1b and 2a O-Antigen Immunogenicity in Mice , 2021, Microorganisms.

[9]  F. Mancini,et al.  Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes , 2021, PLoS neglected tropical diseases.

[10]  F. Mancini,et al.  GMMA-Based Vaccines: The Known and The Unknown , 2021, Frontiers in Immunology.

[11]  F. Necchi,et al.  Development of a Monocyte Activation Test as an Alternative to the Rabbit Pyrogen Test for Mono- and Multi-Component Shigella GMMA-Based Vaccines , 2021, Microorganisms.

[12]  R. Rappuoli,et al.  Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension , 2021, Frontiers in Immunology.

[13]  R. Rappuoli,et al.  Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults , 2021, EClinicalMedicine.

[14]  I. Ferlenghi,et al.  Stability of Outer Membrane Vesicles-Based Vaccines, Identifying the Most Appropriate Methods to Detect Changes in Vaccine Potency , 2021, Vaccines.

[15]  F. Necchi,et al.  Effect of O-Antigen Chain Length Regulation on the Immunogenicity of Shigella and Salmonella Generalized Modules for Membrane Antigens (GMMA) , 2021, International journal of molecular sciences.

[16]  F. Mancini,et al.  Dissecting the contribution of O-Antigen and proteins to the immunogenicity of Shigella sonnei generalized modules for membrane antigens (GMMA) , 2021, Scientific reports.

[17]  C. MacLennan,et al.  Outer membrane vesicle vaccines. , 2020, Seminars in immunology.

[18]  F. Mancini,et al.  Characterization of Competitive ELISA and Formulated Alhydrogel Competitive ELISA (FAcE) for Direct Quantification of Active Ingredients in GMMA-Based Vaccines , 2020, Methods and protocols.

[19]  F. Mancini,et al.  Outer membrane vesicles: moving within the intricate labyrinth of assays that can predict risks of reactogenicity in humans , 2020, Human vaccines & immunotherapeutics.

[20]  F. Necchi,et al.  GMMA and Glycoconjugate Approaches Compared in Mice for the Development of a Vaccine against Shigella flexneri Serotype 6 , 2020, Vaccines.

[21]  F. Necchi,et al.  Development of FAcE (Formulated Alhydrogel competitive ELISA) method for direct quantification of OAg present in Shigella sonnei GMMA-based vaccine and its optimization using Design of Experiments approach. , 2019, Journal of immunological methods.

[22]  E. Marchetti,et al.  Booster Vaccination With GVGH Shigella sonnei 1790GAHB GMMA Vaccine Compared to Single Vaccination in Unvaccinated Healthy European Adults: Results From a Phase 1 Clinical Trial , 2019, Front. Immunol..

[23]  S. Clare,et al.  Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella , 2018, Proceedings of the National Academy of Sciences.

[24]  P. Njuguna,et al.  A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against Shigella sonnei Administered Intramuscularly to Adults from a Shigellosis-Endemic Country , 2017, Front. Immunol..

[25]  P. Chetia,et al.  Emergence of antibiotic resistant Shigella species: A matter of concern. , 2017, Journal of infection and public health.

[26]  O. Finco,et al.  Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe , 2017, EBioMedicine.

[27]  F. Necchi,et al.  Development of a high-throughput method to evaluate serum bactericidal activity using bacterial ATP measurement as survival readout , 2017, PloS one.

[28]  S. Muthupandian,et al.  A review on Sero diversity and antimicrobial resistance patterns of Shigella species in Africa, Asia and South America, 2001–2014 , 2016, BMC Research Notes.

[29]  A. Colucci,et al.  Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB , 2015, PloS one.

[30]  G. Dougan,et al.  An O Antigen Capsule Modulates Bacterial Pathogenesis in Shigella sonnei , 2015, PLoS pathogens.

[31]  Nalini Singh,et al.  Treatment of drug-resistant Shigella infections , 2015, Expert review of anti-infective therapy.

[32]  T. Farag,et al.  Shigella Isolates From the Global Enteric Multicenter Study Inform Vaccine Development , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  G. Sonder,et al.  Breaking the chain of transmission: Immunisation and outbreak investigation , 2013 .

[34]  L. Maggiore,et al.  High Yield Production Process for Shigella Outer Membrane Particles , 2012, PloS one.

[35]  J. Poolman,et al.  Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules , 2011, Expert review of vaccines.

[36]  K. Talukder,et al.  Differential Host Immune Responses to Epidemic and Endemic Strains of Shigella dysenteriae Type 1 , 2011, Journal of health, population, and nutrition.

[37]  J. Shiloach,et al.  Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. , 2010, Vaccine.

[38]  M. Mathan,et al.  Effects of zinc supplementation as adjunct therapy on the systemic immune responses in shigellosis. , 2005, The American journal of clinical nutrition.

[39]  D. Cohen,et al.  Prospective Cohort Studies of Shigellosis During Military Field Training , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[40]  B. Wanner,et al.  One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Snoy,et al.  Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei. , 1991, The Journal of infectious diseases.

[42]  M. Levine,et al.  Inoculum size in shigellosis and implications for expected mode of transmission. , 1989, The Journal of infectious diseases.

[43]  A. A. Reeder,et al.  Antibody-dependent cell-mediated antibacterial activity: K lymphocytes, monocytes, and granulocytes are effective against shigella. , 1980, Journal of immunology.

[44]  Nilay Shah,et al.  Emerging Technologies for Low-Cost, Rapid Vaccine Manufacture. , 2019, Biotechnology journal.

[45]  H. Dupont,et al.  Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. , 1972, The Journal of infectious diseases.